News

IMI launches €196m project
Enlarge image

FundingBelgiumEUGermany

IMI launches €196m project

08.02.2013 - The EU’s IMI has launched a novel platform for drug screening. It is aimed at screening 500,000 compounds to find new lead structures.

Under the umbrella of the European Lead Factory, an international consortium of 30 partners led by German Bayer Pharma AG and Taros Chemicals GmbH & Co KG will screen 300,000 compounds provided by seven pharma companies: Bayer, AstraZeneca AB, H. Lundbeck A/S, and Janssen Pharmaceutica NV, Merck KGaA, Sanofi, and UCB Pharma SA. Additionally, the academic and SMEs will synthesise a library of 200,000 completely novel compounds. The pharma companies will screen this new chemical space.

Additionally, the academic and SME partners will screen the compound library with their own assays generating new IP within a newly established European Screening Centre. The EU will fund the project with €80m. The Joint European Compound Collection will be accessible to all project partners and to public organisations offering promising new targets for drug discovery screening.

„The seven EFPIA partners will, for the first time, open their compound libraries for public researchers“, Taros’ CEO Dr Dimitrios Tzalis told EuroBiotechNews. „This open access approach is a novelty and may lead to significant progress in the field of drug development.“ Hanno Wild, Senior VP and Head of Candidate Generation & Exploration at Project Coordinator Bayer HealthCare Global Drug Discovery, says: ‘The European Lead Factory is an outstanding example of a project in which public-private partnerships enable collaborative drug discovery.“ The Innovative Medicines Initiave is a industry-driven Public Private Partnership between the European Commission and the EU pharma association EFPIA that aims to boost productivity of drug development.

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/imi-launches-eur196m-project.html

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)9.85 SEK15.20%
  • ZEALAND PHARMA (DK)158.00 DKK12.86%
  • ERYTECH PHARMA (F)36.51 EUR6.13%

FLOP

  • FLAMEL TECHNOLOGIES (F)23.00 USD-10.47%
  • ZELTIA (E)3.69 EUR-8.44%
  • WILEX (D)3.28 EUR-6.29%

TOP

  • IXICO (UK)35.00 GBP55.6%
  • DBV TECHNOLOGIES (F)79.73 EUR53.7%
  • ZEALAND PHARMA (DK)158.00 DKK43.0%

FLOP

  • BIOTEST (D)25.73 EUR-63.2%
  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • BIOTECH PHARMACON (N)9.47 NOK-44.9%

TOP

  • ADOCIA (F)90.49 EUR556.2%
  • FORMYCON (D)28.68 EUR318.7%
  • DBV TECHNOLOGIES (F)79.73 EUR305.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEOVACS (F)1.02 EUR-70.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-68.6%

No liability assumed, Date: 29.07.2015